- losartan potassium
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Below is a text only representation of the Patient Information Leaflet. The original can be viewed in PDF format using the link above.
The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet are: PL 00025/0338, PL 00025/0374, PL00025/0473.
Cozaar - Comp 50/12.5mg, 100/12.5mg, 100/25mg Film-Coated Tablets
Package leaflet: Information for the patient
COZAAR® COMP 50mg/12.5mg film-coated tablets
COZAAR® COMP 100mg/12.5mg film-coated tablets
COZAAR® COMP 100mg/25mg film-coated tablets
losartan potassium and hydrochlorothiazide
Read all of this leaflet carefully before taking this medicine because it contains important information for you.
What is in this leaflet
1. What Cozaar Comp is and what it is used for
2. What you need to know before you take Cozaar Comp
3. How to take Cozaar Comp
4. Possible side effects
5. How to store Cozaar Comp
6. Contents of the pack and other information
1. What COZAAR COMP is and what it is used for
Cozaar Comp is a combination of an angiotensin II receptor antagonist (losartan) and a diuretic (hydrochlorothiazide). Angiotensin II is a substance produced in the body which binds to receptors in blood vessels, causing them to tighten. This results in an increase in blood pressure. Losartan prevents the binding of angiotensin II to these receptors, causing the blood vessels to relax which in turn lowers the blood pressure. Hydrochlorothiazide works by making the kidneys pass more water and salt. This also helps to reduce blood pressure.
Cozaar Comp is indicated for the treatment of essential hypertension (high blood pressure).
2. What you need to know before you take COZAAR COMP
Do not take Cozaar Comp
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before taking Cozaar Comp.
You must tell your doctor if you think you are (or might become) pregnant. Cozaar Comp is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
It is important to tell your doctor before taking Cozaar Comp:
Children and adolescents
There is no experience with the use of Cozaar Comp in children. Therefore, Cozaar Comp should not be given to children.
Other medicines and Cozaar Comp
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Diuretic agents such as the hydrochlorothiazide contained in Cozaar Comp may interact with other medicines.
Preparations containing lithium should not be taken with Cozaar Comp without close supervision by your doctor.
Special precautionary measures (e.g. blood tests) may be appropriate if you take potassium supplements, potassium-containing salt substitutes or potassium-sparing medicines, other diuretics (“water tablets”), some laxatives, medicines for the treatment of gout, medicines to control heart rhythm or for diabetes (oral agents or insulins).
It is also important for your doctor to know if you are taking:
Your doctor may need to change your dose and/or to take other precautions:
If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Cozaar Comp” and “Warnings and precautions”).
Please also inform your doctor you are taking Cozaar Comp if you will be undergoing a radiographic procedure and will be given iodine contrast media.
Cozaar Comp with food and drink
You are advised not to drink alcohol whilst taking these tablets: alcohol and Cozaar Comp tablets may increase each other’s effects.
Dietary salt in excessive quantities may counteract the effect of Cozaar Comp tablets.
Cozaar Comp tablets may be taken with or without food.
Pregnancy and breast-feeding
You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Cozaar Comp before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Cozaar Comp. Cozaar Comp is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Tell your doctor if you are breast-feeding or about to start breast-feeding. Cozaar Comp is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.
Use in elderly patients
Cozaar Comp works equally well in and is equally well tolerated by most older and younger adult patients. Most older patients require the same dose as younger patients.
Driving and using machines
When you begin treatment with this medication, you should not perform tasks which may require special attention (for example, driving an automobile or operating dangerous machinery) until you know how you tolerate your medicine.
Cozaar Comp contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
3. How to take COZAAR COMP
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will decide on the appropriate dose of Cozaar Comp depending on your condition and whether you are taking other medicines. It is important to continue taking Cozaar Comp for as long as your doctor prescribes it in order to maintain smooth control of your blood pressure.
High Blood Pressure
The usual dose of Cozaar Comp for most patients with high blood pressure is 1 tablet of Cozaar Comp 50 mg/12.5 mg per day to control blood pressure over the 24-hour period. This can be increased to 2 tablets once daily of Losartan / Hydrochlorothiazide 50 mg/12.5 mg Film-Coated Tablets or changed to 1 tablet daily of Losartan / Hydrochlorothiazide 100 mg/25 mg Film-Coated Tablets (a stronger strength) per day. The maximum daily dose is 2 tablets per day of Losartan / Hydrochlorothiazide 50 mg/12.5 mg Film-Coated Tablets or 1 tablet daily of Losartan / Hydrochlorothiazide 100 mg/25 mg Film-Coated Tablets.
The tablets should be swallowed whole with a glass of water.
If you take more Cozaar Comp than you should
In case of an overdose, contact your doctor immediately so that medical attention may be given promptly. Overdose can cause a drop in blood pressure, palpitations, slow pulse, changes in blood composition, and dehydration.
If you forget to take Cozaar Comp
Try to take Cozaar Comp daily as prescribed. However, if you miss a dose, do not take an extra dose. Just resume your usual schedule.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience the following, stop taking Cozaar Comp tablets and tell your doctor immediately or go to the casualty department of your nearest hospital:
A severe allergic reaction (rash, itching, swelling of the face, lips, mouth or throat that may cause difficulty in swallowing or breathing).
This is a serious but rare side effect, which affects more than 1 out of 10,000 patients but fewer than 1 out of 1,000 patients. You may need urgent medical attention or hospitalisation.
The following side effects have been reported:
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Not known (frequency cannot be estimated from the available data):
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
Malta: ADR Reporting at: www.medicinesauthority.gov.mt/adrportal
5. How to store COZAAR COMP
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the container. The expiry date refers to the last day of that month.
Store Cozaar Comp in the original package in order to protect from light and moisture. Do not store the package above 30°C.
Store in the original container in order to protect from light. Keep the bottle tightly closed in order to protect from moisture. Do not store the bottle above 25°C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Cozaar Comp contains
The active substances are losartan potassium and hydrochlorothiazide.
Cozaar Comp 50 mg/12.5 mg contains 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide as the active ingredients.
Cozaar Comp 100 mg/12.5 mg contains 100 mg of losartan potassium and 12.5 mg of hydrochlorothiazide as the active ingredients.
Cozaar Comp 100 mg/25 mg contains 100 mg of losartan potassium and 25 mg of hydrochlorothiazide as the active ingredients.
Cozaar Comp 50 mg/12.5 mg, Cozaar Comp 100 mg/12.5 mg and Cozaar Comp 100 mg/25 mg contain the following inactive ingredients:
microcrystalline cellulose (E460), lactose monohydrate, pregelatinized maize starch, magnesium stearate (E572), hydroxypropyl cellulose (E463), hypromellose (E464).
Cozaar Comp 50 mg/12.5 mg contains 4.24 mg (0.108 mEq) of potassium. Cozaar Comp 100 mg/12.5 mg and Cozaar Comp 100 mg/25 mg contain 8.48 mg (0.216 mEq) of potassium.
Cozaar Comp 50 mg/12.5 mg and Cozaar Comp 100 mg/25 mg also contain titanium dioxide (E171), quinoline yellow aluminum lake (E104) and carnauba wax (E903).
Cozaar Comp 100 mg/12.5 mg also contains: titanium dioxide (E171) and carnauba wax (E903).
What Cozaar Comp looks like and contents of the pack
Cozaar Comp 50 mg/12.5 mg is supplied as yellow, oval film-coated tablets marked 717 on one side and plain or scored on the other. The score line is not intended for breaking the tablet.
Cozaar Comp 100 mg/12.5 mg is supplied as white, oval film-coated tablets marked 745 on one side and plain on the other.
Cozaar Comp 100 mg/25 mg is supplied as light yellow, oval film-coated tablets marked 747 on one side and plain on the other.
Cozaar Comp is supplied in the following pack sizes:
Cozaar Comp 50 mg/12.5 mg - PVC/PE/PVDC blister packages with aluminum foil lidding in cartons containing 4, 7, 10, 14, 20, 28, 30, 50, 56, 84, 98, or 280 tablets and unit-dose packages of 28, 56 and 98 tablets for hospital use. HDPE bottles of 100 tablets.
Cozaar Comp 100 mg/12.5 mg - PVC/PE/PVDC blister packages with aluminum foil lidding in cartons containing 14, 15, 28, 30, 50, 56, 84, 90, 98, 280 tablets. HDPE bottles of 100 tablets.
Cozaar Comp 100 mg/25 mg - PVC/PE/PVDC blister packages with aluminum foil lidding in cartons containing 7, 14, 28, 30, 50, 56, 84, 90, 98, or 280 tablets and unit-dose packages of 28, 56 and 98 tablets for hospital use. HDPE bottles of 100 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
The Marketing Authorisation Holder in the UK and Malta is
50 mg/12.5 mg strength:
100 mg/12.5 mg and 100 mg/25 mg strengths:
This medicinal product is authorized in the Member States of the EEA under the following names:
Member State Invented name
Austria Cosaar plus 50mg/12,5mg
Austria Fortzaar 100mg/25mg
Belgium COZAAR PLUS 50 mg/12,50 mg comprimés pelliculés
Belgium COZAAR PLUS 100 mg/12,50 mg comprimés pelliculés
Belgium COZAAR PLUS FORTE 100 mg/25 mg comprimés pelliculés
Denmark Cozaar Comp.
Denmark Cozaar Comp. 100 mg / 12,5 mg
Denmark Cozaar Comp. Forte
Finland COZAAR Comp
Finland COZAAR Comp Forte
France FORTZAAR 100 mg/25 mg, comprimé pelliculé
France HYZAAR 50 mg/12,5 mg, comprimé pelliculé
France FORTZAAR 100 mg/12,5 mg, comprimé pelliculé
Germany LORZAAR PLUS 50/12,5 mg Filmtabletten
Germany LORZAAR PLUS forte 100/12,5 mg Filmtabletten
Germany FORTZAAR 100/25 mg Filmtabletten
Greece HYZAAR Forte
Greece HYZAAR Extra Forte
Iceland Cozaar Comp
Iceland Cozaar Comp 100 mg/12,5 mg
Iceland Cozaar Comp Forte
Ireland COZAAR Comp 50mg/12.5mg film-coated tablets
Ireland COZAAR Comp 100mg/12.5mg film-coated tablets
Ireland COZAAR Comp 100mg/25mg film-coated tablets
Italy HIZAAR 50 mg + 12,5 mg compresse rivestite con film
Italy HIZAAR 100 mg + 25 mg compresse rivestite con film
Italy FORZAAR 100 mg + 25 mg compresse rivestite con film
Luxembourg COZAAR PLUS 50 mg/12,50 mg comprimés pelliculés
Luxembourg COZAAR PLUS 100 mg/12,50 mg comprimés pelliculés
Luxembourg COZAAR PLUS FORTE 100 mg/25 mg comprimés pelliculés
Malta COZAAR Comp 50/12.5 mg pilloli miksija b’rita
Malta COZAAR Comp 100/12,5 mg pilloli miksija b’rita
Malta COZAAR Comp 100/25 mg pilloli miksija b’rita
Netherlands HYZAAR 50/12,5
Netherlands COZAAR Plus 100/12,5
Netherlands FORTZAAR 100/25
Norway Cozaar Comp
Norway Cozaar Comp Forte
Poland HYZAAR FORTE
Portugal Cozaar Plus
Romania HYZAAR 50 mg/12,5 mg comprimate filmate
Romania FORTZAAR 100 mg/25 mg comprimate filmate
Slovenia HYZAAR 50 mg/12,5 mg filmsko obložene tablete
Slovenia HYZAAR 100 mg/12,5 mg filmsko obložene tablete
Slovenia FORTZAAR 100 mg/25 mg filmsko obložene tablete
Spain COZAAR Plus 50 mg/12,5 mg comprimidos recubiertos con película
Spain FORTZAAR 100 mg/25 mg comprimidos recubiertos con película
Sweden COZAAR Comp 50 mg/12,5 mg filmdragerade tabletter
Sweden COZAAR Comp 100 mg/12,5 mg filmdragerade tabletter
Sweden COZAAR Comp Forte 100 mg/25 mg filmdragerade tabletter
United Kingdom COZAAR COMP 50mg/12.5mg film-coated tablets
United Kingdom COZAAR Comp 100mg/12.5 mg film-coated tablets
United Kingdom COZAAR Comp 100mg/25mg film-coated tablets
This leaflet was last revised in July 2017
© Merck Sharp & Dohme Limited 2017. All rights reserved.